METHOD FOR ESTIMATING RISK OF EXPRESSION OF ADVERSE DRUG REACTION CAUSED BY ADMINISTRATION OF COMPOUND, WHICH IS EITHER METABOLIZED PER SE BY UGT1A1 ENZYME OR WHOSE METABOLIC INTERMEDIATE IS METABOLIZED BY ENZYME

摘要

PPROBLEM TO BE SOLVED: To provide a method for estimating the risk of expression of an adverse drug reaction caused by the administration of irinotecan and a method for reducing adverse reaction caused by administration of irinotecan. PSOLUTION: A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of T1A1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drug reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan. PCOPYRIGHT: (C)2009,JPO&INPIT